Biotech Values

[DewDiligence]

(MNTA TEVA): WPI appears to have dismissed any hope of Amphastar’s obtaining FDA approval for generic Lovenox. Here is what WPI’s CEO, Paul Bisaro, said about Lovenox on today’s CC in reply to a question by Cowen’s Ken Cacciatore:

http://seekingalpha.com/article/190186-watson-pharmaceuticals-inc-q4-2009-earnings-call-transcript

Regarding Lovenox, Ken, I don’t really have enough insight to give you any valuable read on Lovenox. As you know our partner, Amphastar is the one who deals directly with the agency and we don’t really participate in those conversations, so we don’t have the sort of direct hands-on knowledge. I think others like Momenta, Teva have probably more direct knowledge.

LOL